{"name":"Alpha Biopharma (Jiangsu) Co., Ltd.","slug":"alpha-biopharma-jiangsu-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"zorifertinib","genericName":"zorifertinib","slug":"zorifertinib","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"zorifertinib","genericName":"zorifertinib","slug":"zorifertinib","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOWkhTZGJDeXNZOFlURnI1Ui1maEhPaDdSNkJocGdxR0NCZFBZSDNRQ296eFNxS0FyQlZ5NmQwR0plTUU5blR4OHpYSHpBQUpoVE5uUU5VZzZGNmRNSGExLUxiZmNDMFJmTXAtazVhX0JSMDA2QWNacnAxYkJrRjBNcFFoY2puNnNSMHRwajVvdWdETG1EamJncjgteFVqdVR5aENWc3kzWVQ0QQ?oc=5","date":"2026-04-06","type":"trial","source":"Seeking Alpha","summary":"Kailera Therapeutics Pursues IPO On Promising GLP-1 Trial Results (KLRA) - Seeking Alpha","headline":"Kailera Therapeutics Pursues IPO On Promising GLP-1 Trial Results (KLRA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxObTN3R1ZmTjJIbjNzQkFDeFBJQ250bnc0MjV5TURWamtOMkNudklJVFE2WU9waW9rdGRkdUhaQWlnNzhLemw1TVdJRnhOcm1FTGowemdtT2R4NzlpdUZZVWFXZndsbUVOaWRLWDNqVURaWVVfNjJiUWVINkkzR3N0bWdOUllXV3ZhTU1wMXRpRXp6MnF2Z2Iwb2szcXNXSVRYWGlyWXE5c1ZrYjNzLWgxZWc0U0U0YU9lTE9fT1Z4WDNpNk15STRmY05ZVExOY3RSdDVNbVJNYmY0SVNTTzNvNjdCWHRPZXlVVVdZV2hNMENzOUdMcU1MUy1YVGkzcHRLT2paTjR6anhyV1p3b0ZaTV9FOU5mamwxeFYyRzY3ZDBscEtu?oc=5","date":"2026-03-17","type":"trial","source":"StreetInsider","summary":"HER2 Positive Breast Cancer Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight - StreetInsider","headline":"HER2 Positive Breast Cancer Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi8gJBVV95cUxQem1QNkZoLXZKWURKcEVVRTVKMjJ1aTJuMHU2RVJQMTBJN012RTkzbnMtU0FsYkZPOTc4elhjWjJ2OHk3VjZvZDdkdTZfVnIwQ0FGbHNGZVRpUmI3M29XM041ZFhXeS1TMzJVd2lpZ3RkTEU5Rk9NYnhwd0tYcnpkcTFyYkJERHdRUHdRek05T0wzU2lmY3lwUW1CM1pYY1VIRjcxUFdzNXV1aHdSZW82MEljYjg0NFFYbEFSQTJXMWNDSXJjT0UwOWJONkxtUTNoZWlEY1VZWHl0c000NGcyLWxGd0RQdURFWnVweDBYTWNYbndfVU9Od2laVXVUZzJmdG03dFRvbVRVNE1maVdFWG5PbmxGMzRIODdKb0NrSlE3a24xUlQ0N3o2ZFNHbVhyOEN3d2tZZ3BZeHozVVhLYTBaY1kxVWpXV09wc0NOREhQRG92T3Q2RkplOFlqMUkxejFrOWlGNDRVRUJJRVpuU3dB?oc=5","date":"2026-03-12","type":"pipeline","source":"globenewswire.com","summary":"Pharmaceutical and Biotechnology Royalty Rates Agreements - globenewswire.com","headline":"Pharmaceutical and Biotechnology Royalty Rates Agreements","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-07","type":"regulatory","source":"PR Newswire","summary":"Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | DelveInsight - ","headline":"Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovat","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQYklmVDFUWlh3dUdkdGlYSHRNQzlhck1IMGJZcVg5eFlxdUFaWjJhWXlEc2JBYno3NTZPcmVqY0RwOWh4eWNickZVbXZnVmswTkd5ZnRMMmo3VXN3RzAxQlhQVG91bWJIMms2eF9uRnlscnUzZUJDbmZYNWY0bFNQcWYzRnFtYVcxWHNmT1hzM0h5d0RabmNpazhINA?oc=5","date":"2026-01-02","type":"deal","source":"BioWorld News","summary":"New year sees Abbvie, Zelgen in $1.1B T-cell engager deal - BioWorld News","headline":"New year sees Abbvie, Zelgen in $1.1B T-cell engager deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQWEhwcjFTVEI5WUFRU01KNnd3MWluTDlubzhPMzlCLVViSUF5LVFSRUpNYnFrSEZkWEhoMEJxcDJjSlVTcDlYSDlIaFhCRklBSGE2dUp5eDRCZXpMSWFFLWI1bVc4Y2FLUm9YaGRjYTdXbDVyY1NjZFdKYVk0ZzU0bkVieWFEemhtVXFROHVGQVV0UWgtV2lrdTZqbWhNNHRKZ2c?oc=5","date":"2025-12-09","type":"trial","source":"Seeking Alpha","summary":"Terns Pharmaceuticals: CML Data Blows Wall Street Away - Again (NASDAQ:TERN) - Seeking Alpha","headline":"Terns Pharmaceuticals: CML Data Blows Wall Street Away - Again (NASDAQ:TERN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPV1l4ZHZYUzI0NHE5RVhSLWxhYlBvNTlFaFc5ZDZyakpNQWNPTHliZFBYdWNNWGp0Yk4wXzkxcW5NTXRfT0IxNVY2NUJDaXo5dW9QbnhUTm9hb2lfMnNLNXpOOEFjRGNrR3JSczNjSEtYRDhQX1JTSHc1dkYxTDZFWllFckZOOEZiT1A3LXQ5eUNjdmc3Q3dxcWo4WjZCdw?oc=5","date":"2025-11-25","type":"pipeline","source":"BioWorld News","summary":"Phrontline raises $60M in pre-A+ round for bispecific ADCs - BioWorld News","headline":"Phrontline raises $60M in pre-A+ round for bispecific ADCs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPMGhPdGxVQ2ZhVEN3MkFUXy1rb0VSR3Y3Y3FuWXhzVWdMVmVkdkpHZnZXMWRHcnAyeEVUTVN0X09tRDA3bVdtR2M4M1lVNFo5UXNWWjEzRkNoSjBJS0llaXZNV0VSaEFqOFpvcjFoa0paYkNCZi1HdGR4OHBVY2Y4eGFTNWNLUzFkaHgydjNSRkxiNDdsU2c1WWl1elI0aUNfRmh2c0xYMENfZ0oteDk5c1hRY0swVjVkMjJaMF93eGpSaTBnVFJETjNxMFpSOUx0c1Z5N0VBdlFjYzlpNnhrcGxBbFAzZ20ycVE?oc=5","date":"2025-04-15","type":"pipeline","source":"PR Newswire","summary":"Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight - PR Newswire","headline":"Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxPU3RGMlFjcVVhSnVqOE1mbUlPNEtjOEU2V1hlNG05czhRZ3B1MkZRY0pTTHR5UEFqQTlJUnYyOUI1N0lodDl5N1V2S1NRQ0VmdkdVVTRHa1hpTmVPeTZ3eUVlV1lFREV1ZlFkMmpPZkZ5WWFCSDFQSU8wdER1ZXI2R25LWl80Q3ZGVm9OU24xd2I0VENzcVlUc0NlUHhZektWNldUR01ZNUdlYTNyNV9uLUJvUjc5dXBDMU1YTTlYeFNPVVFSRHRPLUgxQVRFZ2tSVWpTVlk1MGg4WTdDTzBnVXh0NV9ELW5sVFlBNG5IdzJsX0JvWkZoRkx6eThJRHRZQmUxMXZkYlFnMzZCX1p3X2x6U3hEUE90eERTZmwyV1Fhd2R2a2lMT184UVMzckdjNFVscENEMUFzbjdJaUgyUzBYcG5SRUk3V0w4dWhBTVhNWVU?oc=5","date":"2025-03-31","type":"regulatory","source":"Barchart.com","summary":"Rheumatoid Arthritis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Eli Lilly and Company, Philogen, I-Mab Biopharma Co. Ltd., Teijin Pharma -","headline":"Rheumatoid Arthritis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFB2ZGJvWmFFLVVfQk1IZ2txa3l3TnJZc0cxOFhhVGwzQWNTNWR2cGFwX0wwNmhNenA1cjFXV012eWtWbDBBUVFpdEdwNVMyQ3ZheUYza1dGUHFfdzlId1pER3dHaHAxY3ZEdktTcHBB?oc=5","date":"2024-10-30","type":"deal","source":"Law.asia","summary":"CSPC signs an exclusive license agreement with Jiangsu Alphamab for the development and commercialization of JSKN003 in mainland China - Law.asia","headline":"CSPC signs an exclusive license agreement with Jiangsu Alphamab for the development and commercialization of JSKN003 in ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNelczaWhmb0RTVGVqakxyT2RLdHlMWkt4dXRtUlJLckNVNXVTREJuMW9nTlB4WHI3em82RnRjUG1RMUFPYkRRZkoyUVB4eWNpZFFzbnJUNUwydUk5dTFrZEpEQlNFb1NhRHlwT2VSZTN6UHI3WEg2cjBaZ0dJNEc4NzJaWW5JXzJOZFE?oc=5","date":"2024-01-25","type":"deal","source":"pharmaphorum","summary":"Glenmark licenses cancer drug from China’s Alphamab, 3D Med - pharmaphorum","headline":"Glenmark licenses cancer drug from China’s Alphamab, 3D Med","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-01-25","type":"pipeline","source":"The Economic Times","summary":"Glenmark inks licensing pact with Jiangsu Alphamab, 3D Medicines for cancer drug - The Economic Times","headline":"Glenmark inks licensing pact with Jiangsu Alphamab, 3D Medicines for cancer drug","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}